2015
DOI: 10.1001/jamaophthalmol.2015.3359
|View full text |Cite
|
Sign up to set email alerts
|

Ocular Surface Squamous Neoplasia

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2019
2019
2021
2021

Publication Types

Select...
3
1

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 8 publications
0
2
0
Order By: Relevance
“…15,36,37 It also stains mast cells, inflammatory cells and injured cells. 38 Gichuhi et al 36 performed a study with 537 participants to determine the safety and accuracy of toluidine 0.05% in distinguishing OSSN from benign lesions. They found that there was no surface toxicity and only a mild discomfort with application of the drops (when used without an anaesthetic).…”
Section: Vital Dyesmentioning
confidence: 99%
“…15,36,37 It also stains mast cells, inflammatory cells and injured cells. 38 Gichuhi et al 36 performed a study with 537 participants to determine the safety and accuracy of toluidine 0.05% in distinguishing OSSN from benign lesions. They found that there was no surface toxicity and only a mild discomfort with application of the drops (when used without an anaesthetic).…”
Section: Vital Dyesmentioning
confidence: 99%
“…Nevus, ocular surface squamous neoplasia (OSSN), primary acquired melanosis (PAM), and melanoma were the four most common diagnoses associated with referral to a large United States tertiary ocular oncology center, in descending order of frequency 1. Distinguishing between benign and malignant lesions is not always straightforward,2,3 and yet it is critical to making correct clinical treatment decisions. Reliable noninvasive diagnosis of ocular surface lesions is becoming particularly important as medical therapies have been effective for select types of tumors 4,5.…”
Section: Introductionmentioning
confidence: 99%